Synthesis and Structure-Activity Relationship of Tetra-Substituted Cyclohexyl Diol Inhibitors of Proviral Insertion of Moloney Virus (PIM) Kinases
- J Med Chem. 2020 Dec 10;63(23):14885-14904. doi: 10.1021/acs.jmedchem.0c01279.
- 1. Novartis Institutes for BioMedical Research, Emeryville, California 94608, United States.
- 2. Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States.
- 3. BeiGene, Ltd., San Mateo, California 94403, United States.
- 4. Boston Analytical, Salem, New Hampshire 03079, United States.
- 5. Kite, a Gilead Company, Emeryville, California 94608, United States.
- 6. Crystallographic Consulting, Berkeley, California 94704, United States.
- 7. Exelixis, Alameda, California 94502, United States.
- 8. St. Jude Children's Research Hospital, Memphis, Tennessee 38105, United States.
- 9. Genfleet Therapeutics, Inc., Pudong District, Shanghai 201203, China.
- 10. Pharmacyclics, an AbbVie Company, Sunnyvale, California 94085, United States.
- 11. Recursion Pharmaceuticals, Salt Lake City, Utah 84101, United States.
- 12. Astex Pharmaceuticals Inc., Pleasanton, California 94588, United States.
- 13. Global Blood Therapeutics, South San Francisco, California 94080, United States.
- 14. ORIC Pharmaceuticals, South San Francisco, California 94080, United States.
- 15. Bristol Myers Squibb, Redwood City, California 94158, United States.
- 16. Circle Pharma, Inc., South San Francisco, California 94080, United States.
- 17. Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, United States.
Overexpression of Pim 1, 2, and 3 kinases is frequently observed in many malignancies. Previously, we discovered a potent and selective pan-PIM kinase inhibitor, compound 2, currently in phase I clinical trials. In this work, we were interested in replacing the amino group on the cyclohexane ring in compound 2 with a hydroxyl group. Structure-based drug design led to cellularly potent but metabolically unstable tetra-substituted cyclohexyl diols. Efforts on the reduction of Log D by introducing polar heterocycles improved metabolic stability. Incorporating fluorine to the tetra-substituted cyclohexyl diol moiety further reduced Log D, resulting in compound 14, a cellularly potent tetra-substituted cyclohexyl diol inhibitor with moderate metabolic stability and good permeability. We also describe the development of efficient and scalable synthetic routes toward synthetically challenging tetra-substituted cyclohexyl diol compounds. In particular, intermediate 36 was identified as a versatile intermediate, enabling a large-scale synthesis of highly substituted cyclohexane derivatives.